Healthy volunteers vs. patients [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2011-06-24 17:40 (5483 d 22:06 ago) – Posting: # 7171
Views: 6,668

Dear Marcel!

❝ When choosing a dose for the conduct of a bioequivalence study, is it your understanding that one should move from highest dose to lowest dose (or highest tolerable dose) in healthy subjects before moving to patients?


I’m not sure what you mean by ‘…before moving to patients’. While in the draft GL EMA suggested to assess BE in the highest dose stated in the innovator’s SmPC, the current GL (Section 4.1.6) recommends (if linear PK applies) the highest strength. For highly soluble drugs a lower strength is also acceptable. For non-linear PK, it depends on the type of non-linearity; see the respective section.

❝ As well, can you expand on your statement that healthy volunteers allow for better standardization?


Essentially two points:

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
307 visitors (0 registered, 307 guests [including 23 identified bots]).
Forum time: 15:46 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5